Approved & therapeutic
Histrelin
Supprelin LA, Vantas
Histrelin is a GnRH agonist delivered by a subcutaneous implant that releases continuously for twelve months, approved for central precocious puberty and previously for advanced prostate cancer.
Also known as: Supprelin LA, Vantas, histrelin acetate
- Status
- Histrelin is approved by the U.S. FDA and has official prescribing information.
- Evidence
- Approved labeling. Official prescribing information exists, based on clinical trials in people.
- Half-life
- The implant releases continuously over 12 months; circulating histrelin is cleared within hours of removal.
- How it's taken
- Subcutaneous implant in the inner upper arm, replaced every 12 months
- Mechanism
- Reproductive axis (GnRH / kisspeptin / oxytocin)
- Pathways
- GnRH, Androgen, Estrogen
How Histrelin works
Histrelin is a potent GnRH agonist. Sustained release from the implant produces continuous receptor exposure, downregulating pituitary GnRH receptors and suppressing LH, FSH and downstream sex steroids for the life of the implant.
What research has looked at
- A single implant provides twelve months of suppression, removing the adherence burden of monthly or quarterly injections — a substantial advantage in children requiring years of therapy.
- Reliably suppresses the pituitary-gonadal axis in central precocious puberty and preserves adult height potential.
- Suppression is reversible: pubertal progression resumes after implant removal.
Evidence level: Approved labeling. Official prescribing information exists, based on clinical trials in people. These are areas studied or reported, not promised effects.
Reported side effects and risks
- The implant must be surgically inserted and removed under local anaesthesia, and implant breakage during removal has been reported, occasionally requiring additional procedures.
- Initial gonadotropin surge with transient symptom flare.
- Implant-site reactions: pain, bruising, erythema and, less often, infection.
- Decreased bone mineral density with prolonged suppression.
- Headache and hot flashes.
Sources
- FDA approved-drug listing for histrelin · U.S. Food & Drug Administration
- DailyMed prescribing information for histrelin · NIH · DailyMed
- PubMed research on histrelin implant precocious puberty · NIH · National Library of Medicine
- DrugBank record for histrelin · DrugBank
Track Histrelin in Peptide Vault
Log every dose, set reminders on your own schedule, rotate injection sites and keep your vials organized. Peptide Vault records what you enter. It doesn't recommend compounds or doses. iPhone, on-device.
Related compounds
Histrelin FAQ
What is Histrelin?
Histrelin is a GnRH agonist delivered by a subcutaneous implant that releases continuously for twelve months, approved for central precocious puberty and previously for advanced prostate cancer.
How does Histrelin work?
Histrelin is a potent GnRH agonist. Sustained release from the implant produces continuous receptor exposure, downregulating pituitary GnRH receptors and suppressing LH, FSH and downstream sex steroids for the life of the implant.
Is Histrelin FDA approved?
Yes. Histrelin is approved by the U.S. FDA and has official prescribing information. Evidence level: approved labeling. Official prescribing information exists, based on clinical trials in people.
What is the half-life of Histrelin?
Reported half-life: The implant releases continuously over 12 months; circulating histrelin is cleared within hours of removal.
How is Histrelin taken?
Subcutaneous implant in the inner upper arm, replaced every 12 months.
What side effects have been reported with Histrelin?
Reported in the sources: The implant must be surgically inserted and removed under local anaesthesia, and implant breakage during removal has been reported, occasionally requiring additional procedures; Initial gonadotropin surge with transient symptom flare; Implant-site reactions: pain, bruising, erythema and, less often, infection; Decreased bone mineral density with prolonged suppression; Headache and hot flashes.
Educational summary compiled from the sources listed above. Not medical advice. Peptide Vault does not sell, source or recommend any compound. Talk to a qualified clinician before starting or changing anything.